NEW YORK (GenomeWeb News) – Nanosphere on Friday said that it had filed to offer 4.7 million shares of its common stock in a public offering.

The Northbrook, Ill.-based molecular diagnostics firm priced the offering at $7 per share and expects net proceeds of $30.6 million from the offering — or $35.3 million if the over-allotment option of 705,000 shares is exercised. Nanosphere's shares closed Thursday unchanged at $7.65 on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.